Evidence map›Paper›PMID 30332629›Full record

ArticleImmunity2018

The Nuclear Receptor PPARγ Controls Progressive Macrophage Polarization as a Ligand-Insensitive Epigenomic Ratchet of Transcriptional Memory.

Bence Daniel, Gergely Nagy, Zsolt Czimmerer, Attila Horvath, David W Hammers, Ixchelt Cuaranta-Monroy, Szilard Poliska, Petros Tzerpos, Zsuzsanna Kolostyak, Tristan T Hays and 8 more

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Immunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 112 papers.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06168487 phase1recruitingnot on this mapstarted 2024, after this paper: background citation

Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer

TypeinterventionalSponsorTyler J CurielRan2024 to 2027Enrolled36ConditionsProstate CancerArmsTelmisartan, Standard of Care Regimen
NCT06815497 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Phase II Non-Randomized, Unblinded, Single-Center Trial of Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer Versus Historical Best Supportive Care

TypeinterventionalSponsorTyler J CurielRan2026 to 2029Enrolled33ConditionsOvarian CancerArmsTelmisartan
3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 179 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Regulation of immune signal integration and memory by inflammation-induced chromosome conformation.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 5 countries.

Bence DanielSanford-Burnham-Prebys Medical Discovery Institute, Orlando, Florida, USA.
Gergely NagyDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Zsolt CzimmererDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Attila HorvathDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
David W HammersUniversity of Florida, College of Medicine, Myology Institute and Department of Pharmacology and Therapeutics, Gainesville, Florida, USA.
Ixchelt Cuaranta-MonroyDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Szilard PoliskaDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Petros TzerposDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Zsuzsanna KolostyakDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Tristan T HaysSanford-Burnham-Prebys Medical Discovery Institute, Orlando, Florida, USA.
Andreas PatsalosSanford-Burnham-Prebys Medical Discovery Institute, Orlando, Florida, USA.
René HoutmanPamGene International B.V.'s Hertogenbosch, the Netherlands.
Sascha SauerOtto Warburg Laboratory, Max Planck Institute for Molecular Genetics, Berlin, Germany; CU Systems Medicine, University of Würzburg, Würzburg, Germany; Max-Delbrück-Center for Molecular Medicine (BISMB and BIH), Berlin, Germany.
Jean Francois-DeleuzeCentre National de Génotypage, Institut de Génomique, CEA, Evry, France.
Fraydoon RastinejadSanford-Burnham-Prebys Medical Discovery Institute, Orlando, Florida, USA.
Balint L BalintDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
H Lee SweeneyUniversity of Florida, College of Medicine, Myology Institute and Department of Pharmacology and Therapeutics, Gainesville, Florida, USA.
Laszlo NagySanford-Burnham-Prebys Medical Discovery Institute, Orlando, Florida, USA; Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; MTA-DE "Lendulet" Immunogenomics Research Group, University of Debrecen, Debrecen, Hungary. Electronic address: lnagy@jhmi.edu.
University of Debrecen · HUSanford Burnham Prebys Medical Discovery Institute · USUniversity of Florida · USCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRMax Delbrück Center · DEPamGene (Netherlands) · NL

Funding

Training and education CoreU54AR052646 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI MCNALLY, ELIZABETH M, SWEENEY, H LEE · 2005 to 2020
$24.1M
PPARgamma as an architectural regulator of gene expression in endocrine signalingR01DK115924 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI NAGY, LASZLO · 2018 to 2021
$1.6M
NIAMS NIH HHS U54 AR052646NIDDK NIH HHS R01 DK115924Wellcome Trust 210664/Z/18/Z
6 · The paper itself

Abstract

Macrophages polarize into distinct phenotypes in response to complex environmental cues. We found that the nuclear receptor PPARγ drove robust phenotypic changes in macrophages upon repeated stimulation with interleukin (IL)-4. The functions of PPARγ on macrophage polarization in this setting were independent of ligand binding. Ligand-insensitive PPARγ bound DNA and recruited the coactivator P300 and the architectural protein RAD21. This established a permissive chromatin environment that conferred transcriptional memory by facilitating the binding of the transcriptional regulator STAT6 and RNA polymerase II, leading to robust production of enhancer and mRNAs upon IL-4 re-stimulation. Ligand-insensitive PPARγ binding controlled the expression of an extracellular matrix remodeling-related gene network in macrophages. Expression of these genes increased during muscle regeneration in a mouse model of injury, and this increase coincided with the detection of IL-4 and PPARγ in the affected tissue. Thus, a predominantly ligand-insensitive PPARγ:RXR cistrome regulates progressive and/or reinforcing macrophage polarization.

Indexed as

AnimalsCell LineCells, CulturedEpigenesis, GeneticEpigenomicsGene Expression RegulationInterleukin-4LigandsMacrophage ActivationMacrophagesMaleMice, Inbred C57BLMice, Inbred DBAMice, KnockoutPPAR gammaInterleukin-4LigandsPPAR gammacoregulatorsepigenomicsIFN-γIL-4ligand-insensitive enhancersmacrophage polarizationmuscle regenerationNuclear receptorPPARγprogressive polarizationtranscriptional memory

Identifiers

PMID30332629
PMCPMC6197058
OpenAlexW2896474277

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.